文献速递肝病消化道肿瘤与早癌

基于1000例患者15年经验,本机构决定采用钇-90作为肝细胞癌的首选治疗

Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience.
PubMed 文献 · Hepatology · 2018-01-29

这项前瞻性队列研究纳入2003年12月1日至2017年3月31日期间接受钇-90经动脉放射栓塞(TARE)治疗的1000例肝细胞癌(HCC)患者,按Child-Pugh(CP)分级、UNOS和BCLC分期分层报告总生存(OS)及毒性。基于15年1000例经验,研究者决定将TARE作为HCC患者的一线经动脉局部治疗。

要点

  • CP A级患者中,BCLC A、B、C期的删失OS分别为47.3个月、25.0个月、15.0个月。
  • CP B级患者中,BCLC A、B、C期的删失OS分别为27个月、15.0个月、8.0个月。
  • 49例(5%)和110例(11%)患者分别发生3/4级白蛋白和胆红素毒性。

核心结论

  • 基于15年1000例患者的经验,研究者决定将TARE作为HCC患者的一线经动脉局部治疗。

研究设计与样本

  • 前瞻性队列研究,纳入2003年12月1日至2017年3月31日期间接受TARE治疗的1000例HCC患者,并全面回顾毒性和生存结局。

主要发现

  • CP A级患者中,BCLC A期的删失OS为47.3个月(CI 39.5-80.3),BCLC B期为25.0个月(CI 17.3-30.5),BCLC C期为15.0个月(CI 13.8-17.7)。
  • CP B级患者中,BCLC A期的删失OS为27个月(CI 21-30.2),BCLC B期为15.0个月(CI 12.3-19.0),BCLC C期为8.0个月(CI 6.8-9.5)。
  • 49例(5%)患者发生3/4级白蛋白毒性,110例(11%)患者发生3/4级胆红素毒性。
  • 基线特征:CP A级506例(51%)、CP B级450例(45%)、CP C级44例(4%);BCLC A期263例(26%)、B期152例(15%)、C期541例(54%)、D期44例(4%)。

临床怎么用

  • 研究者基于前瞻性数据决定将TARE作为HCC患者的一线经动脉局部治疗,可用作新辅助或确定性治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Yttrium-90 transarterial radioembolization (TARE) is a locoregional therapy (LRT) for hepatocellular carcinoma (HCC). In this study, we present overall survival (OS) outcomes in a 1,000-patient cohort acquired over a 15-year period. Between December 1, 2003 and March 31, 2017, 1,000 patients with HCC were treated with TARE as part of a prospective cohort study. A comprehensive review of toxicity and survival outcomes was performed. Outcomes were stratified by baseline Child-Pugh (CP) class, United Network for Organ Sharing (UNOS), and Barcelona Clinic Liver Cancer (BCLC) staging systems. Albumin and bilirubin laboratory toxicities were compared to baseline. OS outcomes were reported using censoring and intention-to-treat methodologies. All treatments were outpatient, with a median one treatment per patient. Five hundred six (51%) were CP A, 450 (45%) CP B, and 44 (4%) CP C. Two hundred sixty-three (26%) patients were BCLC A, 152 (15%) B, 541 (54%) C, and 44 (4%) D. Three hundred sixty-eight (37%) were UNOS T1/T2, 169 (17%) T3, 147 (15%) T4a, 223 (22%) T4b, and 93 (9%) N/M. In CP A patients, censored OS for BCLC A was 47.3 (confidence interval [CI], 39.5-80.3) months, BCLC B 25.0 (CI, 17.3-30.5) months, and BCLC C 15.0 (CI, 13.8-17.7) months. In CP B patients, censored OS for BCLC A was 27 (CI, 21-30.2) months, BCLC B 15.0 (CI, 12.3-19.0) months, and BCLC C 8.0 (CI, 6.8-9.5) months. Forty-nine (5%) and 110 (11%) patients developed grade 3/4 albumin and bilirubin toxicities, respectively. CONCLUSION: Based on our experience with 1,000 patients over 15 years, we have made a decision to adopt TARE as the first-line transarterial LRT for patients with HCC. Our decision was informed by prospective data and incrementally reported demonstrating outcomes stratified by BCLC, applied as either neoadjuvant or definitive treatment. (Hepatology 2017).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Salem R, Gabr A, Riaz A, et al. Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience. Hepatology. 2018. PMID: 29194711. doi:10.1002/hep.29691

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。